214 related articles for article (PubMed ID: 35339260)
1. Immunotherapy-associated Autoimmune Hemolytic Anemia.
Hwang SR; Saliba AN; Wolanskyj-Spinner AP
Hematol Oncol Clin North Am; 2022 Apr; 36(2):365-380. PubMed ID: 35339260
[TBL] [Abstract][Full Text] [Related]
2. Severe autoimmune hemolytic anemia following immunotherapy with checkpoint inhibitors in two patients with metastatic melanoma: a case report.
Fetter T; Fietz S; Bertlich M; Braegelmann C; de Vos-Hillebrand L; Wenzel J; Heine A; Landsberg J; Jansen P
Front Immunol; 2024; 15():1342845. PubMed ID: 38571955
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy-associated autoimmune hemolytic anemia.
Khan U; Ali F; Khurram MS; Zaka A; Hadid T
J Immunother Cancer; 2017; 5():15. PubMed ID: 28239468
[TBL] [Abstract][Full Text] [Related]
4. Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report.
Ogawa K; Ito J; Fujimoto D; Morita M; Yoshizumi Y; Ariyoshi K; Tomii K; Katakami N
Invest New Drugs; 2018 Jun; 36(3):509-512. PubMed ID: 29340837
[TBL] [Abstract][Full Text] [Related]
5. Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review.
Tanios GE; Doley PB; Munker R
Eur J Haematol; 2019 Feb; 102(2):157-162. PubMed ID: 30347480
[TBL] [Abstract][Full Text] [Related]
6. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
Michot JM; Lazarovici J; Tieu A; Champiat S; Voisin AL; Ebbo M; Godeau B; Michel M; Ribrag V; Lambotte O
Eur J Cancer; 2019 Nov; 122():72-90. PubMed ID: 31634647
[TBL] [Abstract][Full Text] [Related]
7. Managing toxicities associated with immune checkpoint inhibitors.
Park JJ; Arafath S; Kumar ST; Sharma R; Dixit D
JAAPA; 2021 Jun; 34(6):32-39. PubMed ID: 34031312
[TBL] [Abstract][Full Text] [Related]
8. Managing side effects of immune checkpoint inhibitors in breast cancer.
Criscitiello C; Corti C; Pravettoni G; Curigliano G
Crit Rev Oncol Hematol; 2021 Jun; 162():103354. PubMed ID: 34029683
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune haemolytic anaemia in a patient with advanced lung adenocarcinoma and chronic lymphocytic leukaemia receiving nivolumab and intravenous immunoglobulin.
Algaze SD; Park W; Harrington TJ; Mudad R
BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29523604
[TBL] [Abstract][Full Text] [Related]
10. Auto-immune hemolytic anemia and hemophagocytic lymphohistiocytosis as immune-related adverse event in patients with metastatic melanoma and concurrent chronic lymphocytic leukemia: a case series and literature review.
Dirven I; Vander Mijnsbrugge AS; Mignon S; Tijtgat J; Kint N; Neyns B
Melanoma Res; 2023 Aug; 33(4):338-344. PubMed ID: 37114670
[TBL] [Abstract][Full Text] [Related]
11. Type 1 diabetes induced by immune checkpoint inhibitors.
Zhang R; Cai XL; Liu L; Han XY; Ji LN
Chin Med J (Engl); 2020 Nov; 133(21):2595-2598. PubMed ID: 32842016
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and long-term outcomes of warm-type autoimmune hemolytic anemia.
Rattarittamrong E; Eiamprapai P; Tantiworawit A; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Norasetthada L
Hematology; 2016 Jul; 21(6):368-74. PubMed ID: 27077773
[TBL] [Abstract][Full Text] [Related]
13. Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer.
Zhou L; Wei X
Front Immunol; 2021; 12():701951. PubMed ID: 34504488
[TBL] [Abstract][Full Text] [Related]
14. What is the optimal duration of immune checkpoint inhibitors in malignant tumors?
Yin J; Song Y; Tang J; Zhang B
Front Immunol; 2022; 13():983581. PubMed ID: 36225926
[TBL] [Abstract][Full Text] [Related]
15. Advances on immune-related adverse events associated with immune checkpoint inhibitors.
Fan Y; Geng Y; Shen L; Zhang Z
Front Med; 2021 Feb; 15(1):33-42. PubMed ID: 32779094
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis and classification of autoimmune hemolytic anemia.
Bass GF; Tuscano ET; Tuscano JM
Autoimmun Rev; 2014; 13(4-5):560-4. PubMed ID: 24418298
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and management of autoimmune cytopenias in childhood.
Teachey DT; Lambert MP
Pediatr Clin North Am; 2013 Dec; 60(6):1489-511. PubMed ID: 24237984
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.
Le Burel S; Champiat S; Mateus C; Marabelle A; Michot JM; Robert C; Belkhir R; Soria JC; Laghouati S; Voisin AL; Fain O; Mékinian A; Coutte L; Szwebel TA; Dunogeant L; Lioger B; Luxembourger C; Mariette X; Lambotte O
Eur J Cancer; 2017 Sep; 82():34-44. PubMed ID: 28646772
[TBL] [Abstract][Full Text] [Related]
19. Atezolizumab-induced hemolytic anemia - A case report.
Younce CM; Lawton JM; Patel DR
J Oncol Pharm Pract; 2021 Jun; 27(4):1026-1028. PubMed ID: 32951522
[TBL] [Abstract][Full Text] [Related]
20. The Changing Landscape of Autoimmune Hemolytic Anemia.
Barcellini W; Fattizzo B
Front Immunol; 2020; 11():946. PubMed ID: 32655543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
